Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3068361 | 0.84 | GRIK1 (0.49) | AOC3MAPTALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL1205134 | 0.83 | AOC3 (0.43) | AOC3MAPTPOLBALDH1A1KDM4E | |
| SCHEMBL4506884 | 0.82 | GRIK1 (0.45) | AOC3MAPTALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL3082016 | 0.82 | GRIK1 (0.45) | AOC3MAPTALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL927313 | 0.82 | AOC3 (0.46) | AOC3MAPTALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL5493171 | 0.82 | KDM4E (0.51) | AOC3MAPTALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL8118597 | 0.78 | KDM4E (0.45) | AOC3MAPTALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL6594089 | 0.77 | KDM4E (0.46) | AOC3ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL9269321 | 0.76 | GRIK1 (0.56) | MAPTALDH1A1KDM4ESMN1; SMN2GRIK1 | |
| SCHEMBL3073852 | 0.75 | GRIK1 (0.45) | AOC3MAPTALDH1A1KDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9505768-B2 | Compositions and methods for modulating TLR4 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-11-29 | — | — | US | disclosed |
| US-20150197527-A1 | COMPOSITIONS AND METHODS FOR MODULATING TLR4 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2015-07-16 | — | — | US | disclosed |
| US-20090233960-A1 | Kinase Inhibitors | DEVGEN NV (BE) | 2009-09-17 | — | — | US | disclosed |
| US-7417030-B2 | Indazole peptidomimetics as thrombin receptor antagonists | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2008-08-26 | — | — | US | disclosed |
| EP-1934181-A2 | KINASE INHIBITORS | Devgen NV (BE) | 2008-06-25 | — | — | EP | disclosed |
| WO-2007042321-A2 | KINASE INHIBITORS | DEVGEN N.V. (BE) | 2007-04-19 | — | — | WO | disclosed |
| US-7183252-B2 | Indole peptidomimetics as thrombin receptor antagonists | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2007-02-27 | — | — | US | disclosed |
| US-20060166896-A1 | Novel indazole peptidomimetics as thrombin receptor antagonists | ZHANG HAN-CHENG | 2006-07-27 | — | — | US | disclosed |
| US-20060166897-A1 | Novel indazole peptidomimetics as thrombin receptor antagonists | ZHANG HAN-CHENG | 2006-07-27 | — | — | US | disclosed |
| EP-1100492-B1 | INDOLE sPLA2 INHIBITORS | LILLY CO ELI (US) | 2006-05-24 | — | — | EP | disclosed |
| US-6451839-B1 | Indole sPLA2 inhibitors | ELI LILLY AND COMPANY | 2002-09-17 | — | — | US | disclosed |
| US-20020107204-A1 | Method for reducing or preventing the establishment, growth or metastasis of cancer by administering benzimidazolone peptidomimetics PAR-1 antagonist and optionally PAR-2 antagonists | ORTHO-MCNEIL PHARMACEUTICAL CORPORATION | 2002-08-08 | — | — | US | disclosed |
| US-20020103138-A1 | Method for reducing or preventing the establishment, growth or metastasis of cancer by administering indole peptidomimetics PAR-1 antagonist and optionally PAR-2 antagonists | ORTHO-MCNEIL PHARMACEUTICAL CORPORATION | 2002-08-01 | — | — | US | disclosed |
| US-20020037860-A1 | Method for reducing or preventing the establishment, growth or metastasis of cancer by administering indazole peptidomimetics PAR-1 antagonist and optionally PAR-2 antagonists | ORTHO-MCNEIL PHARMACEUTICAL CORPORATION | 2002-03-28 | — | — | US | disclosed |
| EP-1100492-A4 | INDOLE sPLA 2? INHIBITORS | LILLY CO ELI (US) | 2001-10-24 | — | — | EP | disclosed |
| EP-1100492-A1 | INDOLE sPLA 2? INHIBITORS | Eli Lilly & Company (US) | 2001-05-23 | — | — | EP | disclosed |
| WO-2001000659-A1 | BENZIMIDAZOLONE PEPTIDOMIMETICS AS THROMBIN RECEPTOR ANTAGONISTS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2001-01-04 | — | — | WO | disclosed |
| WO-2001000657-A2 | NOVEL INDOLE PEPTIDOMIMETICS AS THROMBIN RECEPTOR ANTAGONISTS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2001-01-04 | — | — | WO | disclosed |
| WO-2001000656-A2 | NOVEL INDAZOLE PEPTIDOMIMETICS AS THROMBIN RECEPTOR ANTAGONISTS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2001-01-04 | — | — | WO | disclosed |
| WO-2000007590-A1 | INDOLE sPLA2 INHIBITORS | ELI LILLY AND COMPANY (US) | 2000-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020107204-A1 | Method for reducing or preventing the establishment, growth or metastasis of cancer by administering benzimidazolone peptidomimetics PAR-1 antagonist and optionally PAR-2 antagonists | F2RL1, F2R, F2RL3 | AOC3 3358/4885MAPT 4237/4885POLB 4215/4885 |
| US-20020037860-A1 | Method for reducing or preventing the establishment, growth or metastasis of cancer by administering indazole peptidomimetics PAR-1 antagonist and optionally PAR-2 antagonists | F2RL1, F2R, F2RL3 | AOC3 3367/4885MAPT 1810/4885POLB 4283/4885 |
| US-20090233960-A1 | Kinase Inhibitors | ROCK1, MAP3K1, MAP3K11 | AOC3 3864/4885MAPT 156/4885POLB 2723/4885 |
| US-20020103138-A1 | Method for reducing or preventing the establishment, growth or metastasis of cancer by administering indole peptidomimetics PAR-1 antagonist and optionally PAR-2 antagonists | F2RL1, F2R, IDO2 | AOC3 3198/4885MAPT 3611/4885POLB 4314/4885 |
| US-20060166896-A1 | Novel indazole peptidomimetics as thrombin receptor antagonists | PTAFR, F2R, F2RL1 | AOC3 3776/4885MAPT 1996/4885POLB 4442/4885 |
| US-20060166897-A1 | Novel indazole peptidomimetics as thrombin receptor antagonists | PTAFR, F2R, F2RL1 | AOC3 3776/4885MAPT 1996/4885POLB 4442/4885 |
| US-20150197527-A1 | COMPOSITIONS AND METHODS FOR MODULATING TLR4 | TLR4, TLR3, TLR6 | AOC3 4590/4885MAPT 3892/4885POLB 4380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.